A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

NCT05975905 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

BIOLOGICAL: Dose A KER-012
BIOLOGICAL: Dose B KER-012
BIOLOGICAL: Dose C KER-012
BIOLOGICAL: Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks

Sponsor

Keros Therapeutics, Inc.